A Study to Assess the Safety and Efficacy of ADVAGRAF (Tacrolimus Modified Release Formulation) in Kidney Transplant Patients Who Were Treated With PROGRAF

Inclusion criteria

• Patients received a kidney transplant at least 12 months ago prior to enrollment.
• Patients have taken unchanged dosage of Prograf® and remained stable serum level of tacrolimus at least for 12 weeks prior to enrollment.
• Patients have kept in unchanged immunosuppressive therapy (combination therapy) at least for 12 weeks prior to enrollment.
• Female patients of childbearing potential must have a negative urine or serum pregnancy test prior to enrollment, and agreed to the deliberate prevention of conception during the trial.
• Patients are considered clinically stable by observer's judgment.
• Patients must understand the purpose and risk of participating the trial and signed on the written consent.

Exclusion criteria

• Patients have previously received an organ transplant other than a kidney.
• Patients have had acute transplant rejection within 12 weeks, or acute transplant rejection requiring antilymphocyte therapy within 24 weeks prior to enrollment.
• Patients newly diagnosed malignant tumors after organ transplant but the patients treated completely with basal or squamous cell carcinoma of the skin are excepted.
• Patients have a known hypersensitivity to Prograf® or tacrolimus.
• Patients whose medical condition are able to interfere with the study objectives.
• Patients who are at the risk of drug abuse or mental disorders or communicate difficulties with the observer.
• Patients have been participated in another clinical trial, or treated with drugs of clinical trial within 28 days prior to enrollment.
• Patients have been taken prohibited combination agents within 28 days prior to enrollment.
• Patients are pregnant or lactating.
• Patient are HIV-positive.
• Patients are not able to keep the scheduled visit.
• Patients whose GFR (MDRD) is in the level of <30 mL/min.
• Patients who are at the condition of 'Creeping creatinine (defined by 20% increase within 6 months prior to enrollment)
• Patients whose SGPT/AST and/or SGOT/ALT levels have been elevated greater than 2 times the upper value of the normal range.
• Patients have FSGS or MPGN Type II as underlying diseases.
• Patients are with cirrhosis